We describe a simple, rapid, specific radioenzymatic assay for "CGS 16617," a new, potent inhibitor of angiotensinconverting enzyme (ACE; EC 3.4.15.1) in human plasma. This assay is based on the principle that the inhibitor (i.e., the drug) binds to the ACE in plasma and hence the amount of free ACE in plasma is inversely related to the amount of active inhibitor present. Free enzyme is reacted with a radiolabeled substrate, and the radioactive product is selectively extracted into the scintillation cocktail for quantification. In recent years, inhibitors of angiotensin-converting enzyme (ACE; dipeptidyl carboxypeptidase I, EC 3.4.15.1) offer a new approach to the treatment of hypertension and congestive heart failure (1, 2). Two prototype compounds, captopril and enalapril, are being marketed, and several others are undergoing clinical investigation (3-7). For improved oral absorption, some of these ACE inhibitors are administered as more lipophilic prodrug esters (3-5), which are hydrolyzed in vivo by esterase to release an active ACE inhibitor.
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In recent years, inhibitors of angiotensin-converting enzyme (ACE; dipeptidyl carboxypeptidase I, EC 3.4.15.1) offer a new approach to the treatment of hypertension and congestive heart failure (1, 2). Two prototype compounds, captopril and enalapril, are being marketed, and several others are undergoing clinical investigation (3) (4) (5) (6) (7) . For improved oral absorption, some of these ACE inhibitors are administered as more lipophilic prodrug esters (3) (4) (5) , which are hydrolyzed in vivo by esterase to release an active ACE inhibitor.
Because of their high potency, most of these ACE inhibitors are therapeutically active at unusually low (nanogram) concentrations in plasma. Their paucity of intrinsic ultraviolet absorbance or fluorescence properties has added to the challenge of monitoring these drugs' concentrations in plasma. The analytical methods currently available for ACE inhibitors include radioimmunoassay (8, 9), gas chromatography/mass spectrometry (10), and liquid or gas-liquid chromatography (11-13) for some relatively less potent inhibitors. Generation of antibodies for use in Development Department, Pharmaceuticals Division, CibaGeigy Corp., Ardsley, NY 10502.
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radioimmunossay requires several months; moreover, many clinical laboratories lack facilities for antibody production or a mass spectrometer to measure concentrations of individual drugs.
The present radioenzymatic assay is based on the principle that the inhibitor (drug) binds to the ACE in plasma and hence the amount of free ACE in plasma is inversely related to the amount of active inhibitor present. Free enzyme is reacted with a radiolabeled substrate and the radioactive product is selectively extracted into the scintillation cocktail for quantification.
The concentration of active ACE inhibitor in plasma is, therefore, measured in the patient's plasma by comparison with a standard curve made from results for additions of analyte to the same patient's blank plasma.
Plasma containing orally administered
prodrugs is hydrolyzedto release the ACE inhibitor, which is then extracted from the sample; the concentrations of the total inhibitor (ester plus acid) are measured after an aliquot of blank plasma is added as the source of enzyme. We hydrolyze the samples with esterases from rat plasma rather than by chemical hydrolysis.
Here we describe the development of a radioenzymatic assay for three ACE inhibitors currently under clinical investigation-pentopril, CGS 14831, and CGS 16617 (Figure 1) . Pentopril, like enalapril, is an ester prodrug that, on hydrolysis, releases an active ACE inhibitor (CGS 13934). Detailed data for CGS 16617 are presented to demonstrate the precision, accuracy, and usefulness of this radioenzyme assay.
Materials and Methods

Reagents and Chemicals
The pH 8.0 assay buffer ("A.C.E. Microvial Buffer"; Ventrex Laboratories, Inc., Portland, ME) contained, per liter, 50 mxnol of HEPES [4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid], 0.1 mol of NaCl, 0.6 mol of Na2SO4, and 1.0 g of sodium azide. The enzyme substrate ("A.C.E. Microvial Substrate"; [3H}hippuryl-glycyl-glycine in pH 8.0 buffer) and the assay scintillation cocktail ("Scintillation Cocktail no. 1"; a mixture of toluene, ethyl acetate, and scintillators) were also purchased from Ventrex Labs. We used "Scintisol" oL-N..._coocH.
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(Isolab Inc., Akron, OH), a scintillation cocktail for 3H and '4C, for determining total-counts radioactivity. All CGS drug compounds were obtained from the Pharmaceuticals Division, Ciba-Geigy Corp., Suffern, NY. plasma. After incubating the samples at 37 #{176}C for 30 mm, we acidified them to pH 1-2 with 50 p1 of phosphoric acid (pH 0.6), then extracted the hydrolyzed metabolite into 4 mL of methylene chloride, vortex-mixed for 30 s, then centrifuged for 10 mm at 500 x g. We transferred 3 mL of the organic (lower) layer to a 12 x 75 mm test tube and evaporated the solvent under nitrogen. After redissolving the residue in 250 pL of iixs buffer and vortex-mixing for 30s, we transferred 200 p1 of this to a microvial and mixed it with 50 p1 of fivefold-diluted blank plasma. This sample, which now contained hydrolyzed metabolite, was then analyzed for active ACE inhibitor as described above.
Calculation of results. We converted dpm to ACE "Activity Units" (AU) by means of equation 1 (14) . To convert AU to percentage inhibition, we used equation 2:
Determination of drug concentration. We plotted standard curve data as AU vs concentration (pg/L), using a computer curve-fitting program (Fit Function, RS/1; BBN Research Systems, Cambridge, MA) to fit the following exponential function for determining the standard curve.
AU=Axec
(3) where A and B are parameters of the exponential standard curve, and "concn"is the concentration of the ACE inhibitor in plasma. Inhibitor concentrations in unknowns were calculated by interpolation from the standard curve. We also used a Michaelis-Menten function (equation 4) to determine the inhibitor concentration in plasma that gave 50% of maximum inhibition (IC50). This function allows the comparison of relative potencies among the ACE inhibitors.
where IM&J is the maximum inhibition. Figure 2 Determination of ACE activity. Standards and samples were analyzed with the A.C.E. Microvial Radioassay Systern, as detailed by the manufacturer. Plasma samples with a drug concentration of more than 2.5 pgfL were diluted with blank plasma to be within the standard curve range of 0.2 to 2.5 zg/L; all plasma standards and samples were diluted fivefold with the HEPES buffer. Triplicate 50-ML aliquota of the diluted standard or sample were added to separate 2.0-mL Wheaton microvials and pre-incubated for 5 mm at 37 #{176}C. Substrate (50 L) was added to each microvial and the incubation continued for 30 mm at 37#{176}C. We stopped the enzyme reaction by adding 50 p.L of 0.5 mol/L HC1 and vortex-mixing.
Results
Comparison of three ACE inhibitors.
After the incubation with ACE substrate was stopped, the samples were allowed to come to room temperature (>10 mm), at which time any product formed (['H]hippuric acid) was separated from unreacted substrate ([3Hjhippuryl-glycyl-glycine)
by addition of 1.5 mL of scintillation cocktail to each microvial and vigorous shaking for 30 s. Under these conditions, approximately 69% of the hippuric acid and less than 1% of the unreacted substrate enter the organic phase. Because radioactivity in the aqueous phase does not interfere with measurement of radioactivity in the organic phase, phase separation is not necessary and the radioactivity in the microvials can be counted immediately after shaking. The assay blank was determined by substituting buffer for the diluted plasma during the 30-mm incubation. Totalcounts of radioactivity per microvial were determined by adding 50 L of substrate and 1.5 mL of Scintisol to triplicate microvials and vortex-mixing for 30 s. We used a Tricarb 4530 liquid scintillation counter (Packard Instrument Co., Downers Grove, IL) equipped for quench correction by external standardization. We assayed all samples and standards in triplicate and used the average disintegrations per minute (dpm) in our calculations.
Hydrolysis of prodrugs. After diluting 50 pL of plasma sample with 200 zL of upxs buffer, we added 100 p1 of rat Day-to-day variability in ACE concentration. Blood sampled from one subject in the placebo portion of a clinical study with CGS 16617 was analyzed to determine the changes in the ACE concentration in plasma during a usual study period. Plasma ACE was measured at 0,8, and 24 hon days 1, 15, and 29. The mean AU was 5.46. The withinsubject CV for enzyme activity was only 5.2%. Changes in activity ranged up to a maximum of 15.3%, which is below Stability of CGS 16617 and ACE activity on storage. Plasma samples (n = 6, each in duplicate) supplemented with CGS 16617 and stored at -70 #{176}C for three months showed a mean (± SD) recovery of 102.8% (± 5.6%) at concentrations ranging from 1.0 to 80.0 sg/L. In addition, plasma samples collected from a normal volunteer after a 20-mg oral dose of CGS 16617 were analyzed once a month for three months. The mean CV was 10.7%, and it did not indicate any instability in either drug concentration or enzyme activity.
Specificity of the radioenzymatic inhibition assay. Concentrations in 64 samples of plasma from four volunteers were also measured by a gas chromatographic-mass spectrometnc procedure (unpublished data, Ciba-Geigy Corp.) and the results compared in order to determine the specificity of the radioenzymatic determination (Figure 4) . The linear relationship between concentrations determined by the two methods, with a slope of 0.93, intercept of almost zero (0.32), and coefficient of determination of 0.97, indicates that the radioenzymatic method is specific for analysis of human plasma samples after oral doses of CGS 16617. A paired ttest analysis also showed no significant difference (p >0.05) in concentrations in plasma as determined by these two methods. 
DiscussIon
Inhibition curves for the three ACE inhibitors we studied show the generality in application of the radioenzymatic method for active ACE inhibitors after appropriate dilution of plasma samples. Although the theoretical maximum inhibition is 100%, the asymptotic estimation of I was as high as 146% for CGS 14831. This is because the maximum inhibition measured was only about 80%. Above 80% inhibition, the error in estimation of free enzyme activity is relatively high because of the asymptotic nature of the inhibition curve. The coefficient of determination of the regression line determined within the range 0 to 80% inhibition, however, is quite high (multi r2 >0.999). The estimated ICsc, the concentration for 50% of maximum inhibition, indicated that the potencies of the three ACE inhibitors were in the order CGS 16617 > CGS 14831> CGS 13934. More than 75% of plasma ACE activity is inhibited at plasma CGS 16617 concentrations of 1-2 ,ugfL.
As seen in Figure 3 , the percent inhibition of ACE activity in plasma after hydrolysis of pentopril was comparable with that for supplemented metabolite (CGS 13934), suggesting that conversion of pentopril on hydrolysis is complete, while cross reactivity of the intact prodrug, pentopril, was minimal. Even at a pentopril concentration of 1000 g/L, the enzyme activity was not appreciably inhibited (<10%). Because of the incomplete recovery of the hydrolyzed inhibitor during extraction, the sensitivity of this method is slightly less than in situ determination of the active ACE inhibitor. Use of the esterase in rat plasma to hydrolyze the prodrug gave more consistent results than did chemical hydrolysis with sodium hydroxide.
Swanson et al. (15) recently reported a similar method based on radioenzymatic assay. In contrast to our method of direct monitoring of the active ACE inhibitor concentration in untreated plasma, their method requires precipitation of endogenous ACE followed by the addition of exogenous ACE and separation of the aqueous phase from water-immiscible scintillation cocktail. In contrast to their study, in our method the standard curve for CGS 16617 is plotted as enzyme activity, rather than % inhibition, versus concentration. This has the advantage that each data point is directly measured and is not influenced by any error in the measurement of activity in blank plasma (equation 2). This method also allows logarithmic transformation to linearize the standard curve instead of the required nonlinear regression of a Michaelis-Menten function.
The in situ determination of the active inhibitor concentration in plasma is simple, rapid, and accurate. The method requires no expensive instrument such as a mass spectrometer or liquid-or gas-chromatograph, or expertise in any unusual analytical technique. The method involves several dilution steps and incubation at 37#{176}C followed by measurement of the radioactivity of the product in a scintillation counter.
An average of 30 plasma samples, each in triplicate, can be analyzed each day by an analyst using standard hand pipettors. Although the method has been developed with triplicate runs for each sample, duplicate analysis would suffice for the necessary accuracy of determination and
